Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Beyond Air’s dense biotech disclosures? Clinical-stage filings can run hundreds of pages, packed with trial data, FDA risk factors, and nitric-oxide science that’s easy to miss. Our platform surfaces what matters—from LungFit™ revenue projections to cash runway assumptions—without forcing you to sift through every footnote.
Stock Titan’s AI reads every new document the moment it hits EDGAR. Get instant clarity on a Beyond Air quarterly earnings report 10-Q filing, line-item R&D expenses, or the exact wording of a Beyond Air 8-K material events explained notice. Need to follow management moves? Real-time alerts flag Beyond Air insider trading Form 4 transactions so you can monitor buying or selling before key clinical updates. Our AI-powered summaries translate technical language into plain English, turning “understanding Beyond Air SEC documents with AI” from wishful thinking into a daily workflow.
Every filing type is covered: the Beyond Air annual report 10-K simplified spells out regulatory pathways and market size estimates; Beyond Air proxy statement executive compensation reveals how bonuses hinge on trial milestones; and Beyond Air earnings report filing analysis highlights quarter-over-quarter cash burn. You’ll also find a full log of Beyond Air Form 4 insider transactions real-time and downloadable exhibits for deeper due diligence. Save hours, spot red flags early, and make confident calls on XAIR—all with AI guidance and continuously updated data.
Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.
The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.
Beyond Air (XAIR) disclosed an insider derivative change by CEO and Chairman Steven A. Lisi. On 11/03/2025, he canceled 164,778 warrants with a $7.586 exercise price and received a replacement warrant for 164,778 shares at $1.95. The warrant was originally issued on September 27, 2024, became exercisable on November 22, 2024, and will expire five years from November 22, 2024. Following these transactions, he directly holds 164,778 warrants.
Beyond Air (XAIR) announced new financing and equity arrangements. The company entered an equity purchase agreement with Streeterville Capital for up to
Beyond Air also issued a secured promissory note with a principal amount of
The company amended a prior loan to add a
Beyond Air, Inc. (XAIR) filed an S-3 shelf registration that includes an At-The-Market (ATM) equity program with BTIG allowing up to $35,000,000 of Common Stock sales. The company agreed to pay the agent a 3.0% cash commission and reimburse certain expenses. Reported issuances under the ATM were 564,699 shares for $2.5 million during the quarter ended June 30, 2025, and 1,877,076 shares for $5.8 million from July 1, 2025 through September 24, 2025. The prospectus includes standard risk-factor language noting the company expects to incur losses for the next few years and lists typical commercialization, regulatory, intellectual property, personnel, and growth-management risks.
Beyond Air, Inc. filed an 8-K describing terms that limit the number of common shares issuable on exercise of certain warrants to prevent a holder from exceeding a stated "Beneficial Ownership Limitation." If an exercise would push the holder past that limit, the company will only issue the number of shares that keep the holder below the limit and will hold the remaining shares in abeyance until the holder notifies the company that issuance would comply with the limitation.
The filing lists exhibits including a Form of New Warrant, a Form of Inducement Letter, and a Press Release dated September 8, 2025. The filing also identifies Steven A. Lisi by name.
Robert Scott Goodman, a director of Beyond Air, Inc. (XAIR), received a grant of stock options on 08/14/2025. The option grant is for 3,750 stock options with an exercise price of $2.45 per share and an expiration date of 08/14/2035. The option vests 25% on December 31, 2025, with the remainder vesting in equal annual installments on each December 31 for the next three years. After the grant, the reporting person beneficially owns 5,750 shares of common stock, which includes an additional 2,000 stock split-adjusted shares noted in the filing.
Balyasny Asset Management and affiliated entities disclose beneficial ownership of 12,290,913 shares of Beyond Air common stock, representing approximately 9.99% of the outstanding class based on the issuer's reported share count. The reported position includes 8,956,504 shares issuable upon exercise of warrants, but a contractual 9.99% blocker prevents the Reporting Persons from exercising any warrants that would result in ownership above 9.99%.
The filing states each Reporting Person has sole voting and dispositive power over the 12,290,913 shares and identifies ADMF as the direct holder and an investment management client of BAM with rights to dividends and sale proceeds. Filers certify the securities were acquired in the ordinary course of business and not to influence control.